Withaferin A (WFA) inhibits tumor growth and metastasis by targeting ovarian cancer stem cells

• DOI: 10.18632/oncotarget.20170
• Publication Date: 2017-08-11T13:17:58Z
• Authors: Sham S. Kakar; Seema Parte; Kelsey Carter; Irving G. Joshua; Christopher Worth; Pranela Rameshwar; Mariusz Z. Ratajczak
• Keywords: 0301 basic medicine; 03 medical and health sciences; Research Paper; 3. Good health

// Sham S. Kakar 1, 2 , Seema Parte Kelsey Carter 1 Irving G. Joshua Christopher Worth Pranela Rameshwar 3 and Mariusz Z. Ratajczak 4 Department of Physiology, University Louisville, KY 40202, USA James Graham Brown Cancer Center, Medicine, Hematology/Oncology, Rutgers, New Jersey Medical School, Newark, NJ 07103, Correspondence to: Kakar, email: [e-mail] Keywords: cancer stem cells, ALDH1, ovarian cancer, withaferin A, securin Received: May 09, 2017     Accepted: June 26, Published: August 10, 2017 ABSTRACT Ovarian is the fifth leading cause deaths due to among women in United States. In 2017, 22,440 are expected be diagnosed with 14,080 will die it. Currently used chemotherapies (Cisplatin or platinum/taxane combination) targets but spares cells (CSCs), which responsible for tumor relapse recurrence cancer. Aldehyde dehydrogenase I (ALDH1) positive one major populations have been related progression metastasis. our studies, we observed expression ALDH1 both surface epithelium (OSE) cortex high levels OSE normal ovary benign (BN) tumor, compared borderline (BL) grade (HG) tumors. contrast, were BL HG tumors BN tumor. Withaferin A (WFA) alone combination cisplatin (CIS) significantly inhibited spheroid formation (tumorigenic potential) isolated CSCs vitro reduced its collected from mice bearing orthotopic control. Treatment animals CIS increased CSC population tumors, suggesting that undergo amplification. WFA suppresses an “oncogene”, may serve as a downstream signaling gene mediate antitumor effects WFA.